Quest Diagnostics reported second-quarter earnings of $3.12 per share, surpassing the Zacks Consensus Estimate of $2.81 per share and representing an 11.03% earnings surprise. This marks the fourth consecutive quarter the medical laboratory operator has beaten consensus EPS estimates. The company posted revenues of $3.04 billion for the quarter ended June 2026, exceeding estimates by 2.15%. This compares to year-ago revenues of $2.76 billion. Quest Diagnostics shares have risen approximately 20.9% since the beginning of the year, outperforming the S&P 500's 9.6% gain. The favourable earnings estimate revision trend has earned the stock a Zacks Rank #2 (Buy) rating. Analysts currently expect earnings of $2.80 per share on revenues of $3.02 billion for the coming quarter.

Quest Diagnostics reported strong second-quarter 2026 results and raised its full-year guidance. The diagnostic information services provider saw revenues increase over 10% to $5.94 billion, driven primarily by organic growth across physician, hospital, and consumer channels. Adjusted diluted earnings per share grew over 19%. Requisition volume surged 13.1% in the quarter, whilst revenue per requisition declined 2.8%. The company experienced double-digit revenue growth in Advanced Diagnostics, including Alzheimer's blood tests and cardiometabolic testing. Quest raised its full-year revenue guidance to $11.95–$12.05 billion, up from $11.78–$11.90 billion previously. The company now expects adjusted diluted EPS of $11.55–$11.85, compared to prior guidance of $11.15–$11.45. Chairman and CEO Jim Davis attributed the performance to focused execution of the company's strategy to deliver innovative testing and actionable health insights.

Your smartwatch may know something your doctor does not - and the American Academy of Neurology just said so. Margaret Osei started wearing an Oura Ring two years ago because her migraines were getting worse and nobody could tell her why. She tracked her sleep. She tracked her temperature. She tracked her heart rate variability - the tiny fluctuations between heartbeats that signal how well your nervous system is recovering. Over time, a pattern emerged. Her worst migraine days almost always followed two nights of fragmented sleep, paired with a small temperature spike linked to her hormonal cycle. Her neurologist had never seen that pattern. Margaret's ring had been watching for it the whole time. What just changed - and why it matters to you. In April 2026, the American Academy of Neurology issued formal guidance on wearable health devices - the first time the organization had addressed how patients and doctors should use this data together. The guidance was reported on by NPR and represents a significant shift in how the medical establishment views the smartwatch on your wrist. Data Management The core message: bring your data to your appointments. Not weeks of raw numbers - patterns. The story behind the numbers. Dr. Sarah Benish, a neurologist with M Health Fairview in Minnesota and author of the new AAN guidance, put it plainly. When patients bring wearable data to appointments, she said, it expands how much information doctors can examine. It helps them understand what a patient is experiencing between visits - something that a 15-minute office appointment cannot capture on its own. And sometimes it catches things that nothing else would. Dr. Lucy McBride, a physician in Washington D.C. and author of Beyond the Prescription, described a patient whose Apple Watch flagged a dangerously low heart rate during sleep. That data led him to a cardiologist. The cardiologist gave him a pacemaker. "That was potentially lifesaving," she said. Data Management The market behind the moment. Wearable health technology is not a niche product anymore. The global wearable technology market was valued at $86.78 billion in 2025 and is projected to reach $231.43 billion by 2034. An estimated 614.1 million wearable devices will ship globally in 2026 alone. Wearable medical device shipments reached 160 million units in 2024 - nearly double the 85 million shipped in 2021. The FDA issued revised guidance in January 2026 reducing oversight of low-risk AI-enabled wearables and wellness devices, while simultaneously clarifying that these devices can now direct users to seek healthcare providers when data suggests they should. That combination - less regulatory friction, more clinical integration - is accelerating adoption faster than most people realize. Three categories of wearable users have emerged. The first are performance optimizers - athletes and health-focused individuals using devices like WHOOP, Oura, and Garmin to track sleep architecture, heart rate variability, and recovery. The second are lifestyle trackers - everyday users monitoring step counts and resting heart rate. The third, and most clinically significant for older adults, are what researchers call detection users - people whose devices function as a kind of guardian angel, monitoring for irregular heart rhythms, falls, and abnormal patterns that might signal something serious before symptoms appear. The states where this information matters most. Not every American has equal risk when it comes to the conditions wearables detect best - and geography plays a real role in that picture. Atrial fibrillation, the irregular heart rhythm that wearables are particularly good at flagging, has dramatically higher prevalence in states with older populations and higher rates of cardiovascular risk factors. Mississippi, West Virginia, Alabama, and Louisiana consistently rank among the highest in the country for heart disease mortality. Oklahoma, Arkansas, and Kentucky are not far behind. These are also states where access to cardiologists and specialists can be limited - where the distance between a rural resident and a cardiac specialist is measured in hours, not minutes. A wearable that detects an irregular heart rhythm and prompts someone to call their doctor is doing something that no office visit can do: it is watching continuously, 24 hours a day, in a way that no healthcare system has the capacity to replicate. Oura has signed a partnership with Counsel Health allowing members to connect their ring data directly with board-certified physicians for clinical questions. WHOOP has integrated with Quest Diagnostics, allowing users to combine wearable biometrics with lab panel results for a more complete health picture. These are not fitness features. They are the early infrastructure of continuous, preventive health monitoring at scale. What the devices are actually watching. The metrics that matter most for longevity are not the ones most people think about. Step count is a proxy. The deeper signals are heart rate variability - a measure of how well your nervous system adapts to stress and recovers from exertion - sleep staging, resting heart rate trends, skin temperature, and respiratory rate. A single bad night means nothing. A two-week trend of declining heart rate variability combined with rising resting heart rate and disrupted deep sleep is a different story entirely. The Apple Watch asthma study - a randomized controlled trial backed by Apple and Elevance Health - showed that wearable-guided management led to meaningfully improved asthma control scores, particularly among patients who had previously struggled to recognize when their condition was worsening. The wearable saw the deterioration coming before the patient did. Smart rings have emerged as a particularly practical form factor for older adults who find watches uncomfortable during sleep - which is when some of the most important data is captured. The Oura Ring 5 monitors heart rate variability, body temperature trends, respiratory rate, and detailed sleep staging through the night. The form factor is discreet, the battery life is measured in days not hours, and there is no screen to create anxiety around the numbers. The honest caution. Wearables are not a replacement for medical care, and the guidance from the AAN is clear on this point. Dr. McBride cautions against arriving at a doctor's appointment with weeks of uncontextualized raw data. Report patterns, she says, not individual data points. A week of disrupted sleep after a major life stressor tells a story. One bad night does not. The data needs to be connected to life - to stress, to illness, to changes in routine - or it is just numbers. There are also real equity concerns. Pulse oximeter accuracy - the sensor that measures blood oxygen levels - has documented disparities across skin tones. Darker skin can produce less accurate readings from optical sensors. Physicians advise discussing this with your provider before relying on oxygen data for health decisions. And for some people, the data itself becomes a source of anxiety that undermines the health benefits it was meant to support. If checking your recovery score first thing in the morning makes you more stressed rather than less, the device is working against you. The best use of wearable data is the one Margaret Osei discovered: not obsessive monitoring, but patient pattern recognition. A tool that helps you have a better conversation with your doctor. A window into your own biology that the medical system, on its own, does not have the bandwidth to keep open. The American Academy of Neurology just said: bring that window to your next appointment. Your doctor is ready to look through it with you.